Capital Fund Management (CFM)’s Myriad Genetics MYGN Stock Holding History

Capital Fund Management (CFM)’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-44,917	Closed	-$398K	–	2463
2025 Q1	$398K	Sell	44,917 -42,638	-49%	-$512K	﹤0.01%	1873
2024 Q4	$1.2M	Buy	+87,555	New	+$1.62M	﹤0.01%	1699
2020 Q3	–	Sell	-47,292	Closed	-$536K	–	1329
2020 Q2	$536K	Buy	+47,292	New	+$672K	0.01%	868
2018 Q2	–	Sell	-45,586	Closed	-$1.35M	–	2186
2018 Q1	$1.35M	Buy	+45,586	New	+$1.54M	0.01%	1141
2016 Q3	–	Sell	-96,034	Closed	-$2.94M	–	1725
2016 Q2	$2.94M	Buy	+96,034	New	+$3.34M	0.03%	601
2015 Q4	–	Sell	-5,527	Closed	-$207K	–	1659
2015 Q3	$207K	Buy	+5,527	New	+$196K	﹤0.01%	1323
2014 Q1	–	Sell	-56,563	Closed	-$1.75M	–	1879
2013 Q4	$1.19M	Buy	+56,563	New	+$1.43M	0.01%	897

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Capital Fund Management (CFM)'s MYGN Position: Q2 2025 in Review

Capital Fund Management (CFM) sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 44,917 shares — an estimated $398K sold.

Capital Fund Management (CFM) first reported a position in MYGN in Q4 2013 and held it in 7 quarters. The position peaked at $2.94M in Q2 2016. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

Capital Fund Management (CFM) reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 44,917 Myriad Genetics shares in Q2 2025, an estimated $398K.
Capital Fund Management (CFM) first reported a position in Myriad Genetics in Q4 2013 and held it in 7 quarters.
Capital Fund Management (CFM)'s Myriad Genetics position peaked at $2.94M in Q2 2016.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2025, filed 13 Aug 2025.